These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22510355)

  • 1. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
    Lazzarin A; Than S; Valluri SR; Heera J; Mukwaya G
    HIV Clin Trials; 2012; 13(2):83-9. PubMed ID: 22510355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
    Rockstroh JK; Soriano V; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Mukwaya G; Jagannatha S; Heera J; Pineda JA
    HIV Clin Trials; 2015; 16(2):72-80. PubMed ID: 25923596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
    Fätkenheuer G; Nelson M; Lazzarin A; Konourina I; Hoepelman AI; Lampiris H; Hirschel B; Tebas P; Raffi F; Trottier B; Bellos N; Saag M; Cooper DA; Westby M; Tawadrous M; Sullivan JF; Ridgway C; Dunne MW; Felstead S; Mayer H; van der Ryst E;
    N Engl J Med; 2008 Oct; 359(14):1442-55. PubMed ID: 18832245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The maraviroc expanded access program - safety and efficacy data from an open-label study.
    Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
    HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
    Rockstroh JK; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Zhang-Roper R; Wang R; Pineda JA; Heera J
    Antivir Ther; 2017; 22(3):263-269. PubMed ID: 27924779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc.
    Carter NJ; Keating GM
    Drugs; 2007; 67(15):2277-88; discussion 2289-90. PubMed ID: 17927288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
    Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY
    HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
    Crespo M; Navarro J; Moreno S; Sanz J; Márquez M; Zamora J; Ocampo A; Iribaren JA; Rivero A; Llibre JM
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):493-498. PubMed ID: 27061975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
    Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.
    Ha B; Wine B; Rodriguez-Alcantra F; Shaefer M
    HIV Clin Trials; 2012; 13(3):171-7. PubMed ID: 22592097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
    Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.
    Hurt CB; Napravnik S; Moore RD; Eron JJ
    Antivir Ther; 2014; 19(4):415-22. PubMed ID: 24458137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
    Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
    Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
    Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
    J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maraviroc.
    Fadel H; Temesgen Z
    Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.